Age: 68.0
Sex: F
Vaccine: COVID19
Symptoms: Echocardiogram, Ejection fraction, SARS-CoV-2 test, Troponin
Clinical narrative: Acute myocardial infarction; This literature-non-study case was reported in a literature article and describes the occurrence of ACUTE MYOCARDIAL INFARCTION (Acute myocardial infarction) in a 68-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.   LITERATURE REFERENCE: Acute myocardial infarction within 24 hours after COVID-19 vaccination. 2021;S0002-9149(21):00631-7     The patient's past medical history included Nasopharyngeal aspiration (2 separate) and Percutaneous coronary intervention (performed to the LC artery, the patient was free of chest pain after PCI). Concurrent medical conditions included Smoker, Hypertension, Hyperlipidemia and Coronary artery disease (Prior, with no Family History of Premature Coronary Artery Disease).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ACUTE MYOCARDIAL INFARCTION (Acute myocardial infarction) (seriousness criteria hospitalization and medically significant). The patient was hospitalized for 7 days due to ACUTE MYOCARDIAL INFARCTION. At the time of the report, ACUTE MYOCARDIAL INFARCTION (Acute myocardial infarction) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Angiocardiogram: LC 100% (Inconclusive) LC 100% and artery with a globular thrombus and TIMI 0 flow (abnormal) Emergency occluded proximal segment of the left circumflex (LC) artery with a globular thrombus and TIMI 0 flow. On an unknown date, Angiogram: TIMI iii flow (Inconclusive) TIMI III flow. On an unknown date, Body mass index: 46.6 kg/m2 (Inconclusive) 46.6 kg/m2. On an unknown date, ECG signs of myocardial infarction: inferior ST elevation (abnormal) Inferior ST elevation. On an unknown date, Echocardiogram: hypokinesis of the anterolateral and inferolateral (abnormal) hypokinesis of the anterolateral and inferolateral walls and mild hypokinesis (abnormal) mild hypokinesis of the anterolateral and inferolateral walls. On an unknown date, Ejection fraction: 50 (Inconclusive) 50 percent and 60 (Inconclusive) 60 percent. On an unknown date, SARS-CoV-2 test: negative (Negative) negative, on 2 separate nasopharyngeal aspirates. On an unknown date, Troponin: 4714 ng/l (Inconclusive) 4714 ng/L.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter considered ACUTE MYOCARDIAL INFARCTION (Acute myocardial infarction) to be possibly related.    Concomitant medications were not provided by the reporter.  No treatment was provided.  It was reported that acute myocardial infarction with onset less than 24 hours after the first dose of a COVID-19 vaccine. The angiographic features of case was suggestive of acute thrombotic events as the underlying mechanism. Patient was discharged 1 week after admission.  This case concerned of patients 1 and attributed the chest pain to local effects of the vaccine injection.  Based on the current available information and temporal association between the use of the product and the start of events (1 day after vaccination), a causal relationship cannot be excluded. However, patient's age, smoking habit and previous history of hypertension, hyperlipidemia and prior coronary artery disease can be relevant confounders.   This case was linked to MOD-2021-290649 (Patient Link).; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start of events (1 day after vaccination), a causal relationship cannot be excluded. However, patient's age, smoking habit and previous history of hypertension, hyperlipidemia and prior coronary artery disease can be relevant confounders.